Skip to Content
MilliporeSigma
All Photos(1)

Documents

1491300

USP

Oxytocin

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

Posterior pituitary extract, α-Hypophamine, Oxytocic hormone

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C43H66N12O12S2
CAS Number:
Molecular Weight:
1007.19
Beilstein/REAXYS Number:
3586108
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

oxytocin

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

[H]N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)[C@@H](C)CC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O

InChI

1S/C43H66N12O12S2/c1-5-22(4)35-42(66)49-26(12-13-32(45)57)38(62)51-29(17-33(46)58)39(63)53-30(20-69-68-19-25(44)36(60)50-28(40(64)54-35)16-23-8-10-24(56)11-9-23)43(67)55-14-6-7-31(55)41(65)52-27(15-21(2)3)37(61)48-18-34(47)59/h8-11,21-22,25-31,35,56H,5-7,12-20,44H2,1-4H3,(H2,45,57)(H2,46,58)(H2,47,59)(H,48,61)(H,49,66)(H,50,60)(H,51,62)(H,52,65)(H,53,63)(H,54,64)/t22-,25-,26-,27-,28-,29-,30-,31-,35-/m0/s1

InChI key

XNOPRXBHLZRZKH-DSZYJQQASA-N

Gene Information

human ... OXTR(5021)

Looking for similar products? Visit Product Comparison Guide

Amino Acid Sequence

Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 [Disulfide Bridge: 1-6]

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Oxytocin is a nonapeptide hormone that possesses the ability to induce contractions in the smooth muscles of the uterus and the myoepithelial cells in the mammary gland. This hormone is synthetically produced and has a minimum oxytocic activity of 400 USP Oxytocin Units per milligram.

Application

Oxytocin USP reference standard suitable for use in specified USP compendial tests and assays.

Also used to prepare standard preparation during the assay of oxytocin.

Biochem/physiol Actions

Stimulates uterine contraction and lactation; increases Na+ excretion; stimulates myometrial GTPase and phospholipase C.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

This product is part of the USP Biologics program.
Sales restrictions may apply.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 9

1 of 9

Atosiban ≥98% (HPLC)

Sigma-Aldrich

A3480

Atosiban

Carbetocin acetate ≥95% (HPLC)

Sigma-Aldrich

SML0748

Carbetocin acetate

USP

USP

1711100

Vasopressin

Fenbendazole Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1832

Fenbendazole

Praziquantel Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1391

Praziquantel

USP

USP

1703805

Tylosin

Elizabeth C Finger et al.
Neurology, 84(2), 174-181 (2014-12-17)
To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal dementia (FTD). We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible
Yuta Aoki et al.
Brain : a journal of neurology, 137(Pt 11), 3073-3086 (2014-08-26)
Recent studies have suggested oxytocin's therapeutic effects on deficits in social communication and interaction in autism spectrum disorder through improvement of emotion recognition with direct emotional cues, such as facial expression and voice prosody. Although difficulty in understanding of others'
Mikko J Peltola et al.
Emotion (Washington, D.C.), 14(3), 469-477 (2014-04-23)
Recent studies suggest that parental caregiving is associated with adaptive changes in neurocognitive responses to emotional cues and oxytocin function, possibly reflecting the increased need of parents to monitor infants' emotional states. In the current study, we investigated whether the
Elliot C Brown et al.
Psychiatry research, 219(3), 436-442 (2014-07-23)
Patients with schizophrenia suffer from dysfunctional social behaviour. Social approach and avoidance (AA) has been associated with motor responses, as the affective valence and gaze direction of facial stimuli can bias push and pull motor tendencies. The aim of this
Y Aoki et al.
Molecular psychiatry, 20(4), 447-453 (2014-07-30)
The neuropeptide oxytocin may be an effective therapeutic strategy for the currently untreatable social and communication deficits associated with autism. Our recent paper reported that oxytocin mitigated autistic behavioral deficits through the restoration of activity in the ventromedial prefrontal cortex

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service